Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…Abstract Number: 575 • 2018 ACR/ARHP Annual Meeting
Time to Discontinuation of Biologic Therapy By Mechanism of Action in Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort
Background/Purpose: Patients with rheumatoid arthritis (RA) may discontinue their biologic disease modifying antirheumatic drug (bDMARDs) due to non-response, loss of response or adverse events. However,…Abstract Number: 2822 • 2018 ACR/ARHP Annual Meeting
Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis
Background/Purpose: In rheumatoid arthritis (RA), biologics are more efficient in combination with methotrexate (MTX) than in monotherapy. When MTX cannot be used, others csDMARD can…Abstract Number: 597 • 2018 ACR/ARHP Annual Meeting
Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry
Background/Purpose: Biologics in combination with methotrexate (MTX) are being incorporated earlier in rheumatoid arthritis (RA) therapy to prevent long-term damage and maintain patient function. While…Abstract Number: 2878 • 2018 ACR/ARHP Annual Meeting
Phase II Clinical Trials Systematically Overestimate Treatment Effects of Subsequent Phase III Trials in Rheumatoid Arthritis
Background/Purpose: Phase 3 (P3) clinical trials are the mainstay of drug development in all areas of medicine, including rheumatology, allowing to determine safety and efficacy…Abstract Number: 629 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib was approved in December 2014 for RA under Taiwan’s National Health…Abstract Number: 2966 • 2018 ACR/ARHP Annual Meeting
Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study
Background/Purpose: Uric monosodium urate (MSU) depositions are detected by ultrasound (US), and US is included in the ACR/EULAR classification criteria for gout. OMERACT definitions for…Abstract Number: 827 • 2018 ACR/ARHP Annual Meeting
Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events
Background/Purpose: Rheumatoid vasculitis (RV) is a rare systemic inflammatory process affecting small to medium sized blood vessels in patients with rheumatoid arthritis (RA). RV confers…Abstract Number: 887 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate to severe RA in a phase 2b study…Abstract Number: 888 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate-to-severe RA in a phase 2b study (NCT01649999)1. We…Abstract Number: 963 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Here, we report the largest integrated safety analysis of tofacitinib to date…Abstract Number: 1519 • 2018 ACR/ARHP Annual Meeting
Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. We explored characteristics of patients (pts) who discontinued (d/c) open-label, long-term extension…Abstract Number: 1526 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The purpose of this study is to describe the profile of patients…Abstract Number: 1538 • 2018 ACR/ARHP Annual Meeting
Moderate Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Background/Purpose: In rheumatology, we are aware of the possibility to develop adverse drug reactions (ADR) to the widely used Disease Modifying Drugs (DMARD). We are…Abstract Number: 1539 • 2018 ACR/ARHP Annual Meeting
Safety of Methotrexate and Leflunomide Combination Therapy in the Treatment of Rheumatoid Arthritis
Background/Purpose: Best treatment of Rheumatoid Arthritis (RA) requires to begin early, with a tight control, including nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, disease-modifying antirheumatic drugs (DMARDs)…
- 1
- 2
- 3
- …
- 16
- Next Page »